Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated by Analysts at Wolfe Research

Research analysts at Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report issued on Friday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $1,150.00 price target on the biopharmaceutical company’s stock. Wolfe Research’s price target suggests a potential upside of 46.96% from the company’s current price.

Several other equities analysts have also recently weighed in on the stock. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada dropped their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Leerink Partners restated a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Trading Down 2.7 %

NASDAQ REGN opened at $782.51 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $780.95 and a 52 week high of $1,211.20. The business has a 50 day moving average price of $1,000.06 and a 200-day moving average price of $1,035.67. The company has a market cap of $85.99 billion, a price-to-earnings ratio of 19.36, a P/E/G ratio of 3.04 and a beta of 0.15.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.48% of the stock is owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Beacon Investment Advisory Services Inc. grew its stake in shares of Regeneron Pharmaceuticals by 0.7% in the third quarter. Beacon Investment Advisory Services Inc. now owns 27,186 shares of the biopharmaceutical company’s stock worth $28,579,000 after purchasing an additional 198 shares during the last quarter. Benjamin Edwards Inc. boosted its holdings in Regeneron Pharmaceuticals by 12,448.0% in the third quarter. Benjamin Edwards Inc. now owns 3,137 shares of the biopharmaceutical company’s stock valued at $3,298,000 after acquiring an additional 3,112 shares in the last quarter. Bamco Inc. NY purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at $4,731,000. Paloma Partners Management Co raised its holdings in Regeneron Pharmaceuticals by 1,789.2% in the 3rd quarter. Paloma Partners Management Co now owns 625 shares of the biopharmaceutical company’s stock worth $657,000 after purchasing an additional 662 shares in the last quarter. Finally, Kestra Investment Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 48.1% in the 3rd quarter. Kestra Investment Management LLC now owns 616 shares of the biopharmaceutical company’s stock worth $648,000 after purchasing an additional 200 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.